SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

Trump-linked crypto is trending due to intensified community scrutiny over alleged investor losses and accusations of a "pump and dump" scheme, with discussions often focusing on financial "grifting" by the Trump family and broader political controversies.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as escalating Middle East tensions drive oil prices higher, while the company is also poised to significantly boost Venezuelan oil production with an expanded license, fueling widespread bullish sentiment among investors discussing its potential for continued upside in the energy sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its dedicated community rallies for the upcoming 4/20, promoting it as an organic culture coin "like Bitcoin but way higher" that embodies decentralization and the fight for cannabis reform. The token is gaining attention for its strong community backing and perceived outperformance compared to traditional cannabis stocks, despite some online skepticism.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is actively discussed amid heightened Middle East tensions, with many in the community anticipating a significant surge in oil prices and a strong upside for energy stocks, driven by stalled US-Iran talks and concerns over potential disruptions to the Strait of Hormuz.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending due to heightened investor attention following its strategic pivot into AI and 6G infrastructure, notably strengthened by partnerships with NVIDIA and Amazon, which is fueling community excitement about its long-term potential despite short-term price fluctuations.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to heightened geopolitical tensions in the Middle East, with community discussion focused on potential oil supply disruptions in the Strait of Hormuz and the broader impact of a "war premium" on the energy sector.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares (GUSH) is trending as escalating Middle East tensions fuel community speculation on imminent oil supply disruptions, leading to significant call option activity and widespread expectations for a powerful rally across the leveraged energy sector.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending amidst escalating Middle East tensions, including reported strikes and retaliations involving Iran, with the community actively debating whether potential disruptions to global oil flows, particularly through the Strait of Hormuz, will lead to a sustained price rally or if market fears are overblown given potential OPEC+ actions.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the following segments: FPL and NEER. The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEra Energy is trending following news of a $2 billion equity offering, which has introduced dilution concerns and prompted a price pullback. Despite this, community conversation remains focused on NEE's strategic role in powering the growing demand from AI data centers through partnerships with tech giants like Google and Meta.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is actively debated amidst rising geopolitical tensions concerning a potential conflict with Iran and threats to oil supply routes, driving some to anticipate a significant price surge, while others argue that diplomatic efforts, massive global oversupply, and increasing renewable energy adoption will lead to a price decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 12,378 Shares of Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) CEO Matthew Kapusta sold 12,378 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a...

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC uniQure N.V. Securities Fraud Class...

uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 6,217 Shares

uniQure N.V. (NASDAQ:QURE - Get Free Report) CFO Christian Klemt sold 6,217 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of...

uniQure (NASDAQ:QURE) CEO Sells $295,339.08 in Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) CEO Matthew Kapusta sold 12,378 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price...

uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your...

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall...

<ul class="summary-bullets"><li>FDA Commissioner Marty Makary flagged concerns around invasive gene therapies delivered via skull openings.</li><li>Investors initially linked the remarks to uniQure’s AMT-130, a Huntington’s disease gene therapy.</li><li>Regenxbio’s RGX-121 has also faced pressure, including a recent Complete Response Letter and clinical holds.</li></ul>Shares of UniQure, Inc. (QURE) tumbled to a five-month low on Thursday after remarks from U.S. Food and Drug Administration (FDA) Commissioner Marty Makary triggered fears that its Huntington’s disease gene therapy could face fresh regulatory hurdles.However, a growing debate among analysts suggests the comments may not have been aimed at UniQure at all, but rather at Regenxbio, whose own gene therapy program recently received a rejection from the FDA.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> slumped 31% on Thursday, while&nbsp;<a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> gained 2.6%.<h2 class="st-heading-2">FDA Chief Flags Invasive Gene Therapies</h2>In a CNBC interview,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-commissioner-refers-to-rare-disease-drug-with-associated-morbidity-analysts-are-divided-if-makary-meant-regenxbio-or-uniqure-drug/cZTGkouRIRe">Makary defended</a> the FDA’s increasingly cautious stance toward rare disease therapies. He referenced a treatment in which researchers drilled small openings into patients’ skulls to deliver a therapy that ultimately failed to show benefit in a randomized trial and carried safety risks.“I have a lot of sympathy for those patients. There's nothing out there to offer them, but we're not going to go ahead and approve something like that that has morbidity associated with it,” Makary said.Although he did not name a company, investors quickly interpreted the comments as a reference to UniQure’s AMT-130, an investigational gene therapy for Huntington’s disease that is delivered directly into the brain through a neurosurgical procedure.<h2 class="st-heading-2">Analysts Split On Makary’s Target</h2>RBC Capital Markets said the comments appeared to be directed at UniQure’s Huntington’s program. The firm described the situation as “disappointing,” but reiterated its ‘Outperform’ rating and maintained a $45 price target, implying a 163% upside from the stock’s current levels.Stifel took a similar tone, saying the stock’s decline was “understandable,” noting Makary appeared to reference AMT-130 as an example of a therapy the FDA has not supported.However, not all analysts agreed. Leerink argued that the remarks were more likely directed at Regenxbio’s RGX-121 gene therapy than at UniQure’s program.The firm noted Makary seemed to be referencing a therapy that had already undergone regulatory review and failed to demonstrate sufficient effectiveness, which aligns with RGX-121.<h2 class="st-heading-2">UniQure Faces FDA Approval Uncertainty</h2>The latest pressure adds to a shifting regulatory path for AMT-130 in recent months. Last year, UniQure said feedback from the FDA suggested data from its Phase I/II studies may no longer be sufficient to support a biologics license application (BLA), marking a change from earlier guidance.In December, final meeting minutes from a pre-BLA discussion confirmed the agency was unlikely to consider existing trial data as primary evidence for approval. The company said last month that it had scheduled a Type A meeting with the FDA to discuss the data package supporting a potential accelerated approval pathway.The company said it expects to provide a regulatory update once it receives the official meeting minutes.Separately, earlier this month, UniQure reported updated preliminary Phase I/IIa data for its Fabry disease gene therapy AMT-191, showing sustained increases in enzyme activity among treated patients. The therapy has received Orphan Drug and Fast Track designations.<h2 class="st-heading-2">Regenxbio’s RGX-121 Also Under Scrutiny</h2>Regenerxbio’s gene therapy programs have also faced regulatory challenges. Last month, the FDA placed a clinical hold on RGX-111, an investigational gene therapy for Hurler syndrome, and RGX-121, a gene therapy for Hunter syndrome, following a preliminary analysis of a tumor case in a treated patient.Earlier this month, the FDA issued a Complete Response Letter (CRL) for RGX-121, citing concerns including uncertainty around study population definition, external control comparability and use of a surrogate endpoint.While H.C. Wainwright said the CRL was in line with expectations following the earlier clinical hold, Morgan Stanley said the decision cited insufficient evidence of effectiveness and highlighted uncertainty around the regulatory path forward.<h2 class="st-heading-2">FDA Opens Door For Tailored Gene Therapies</h2>Makary’s remarks also came shortly after the FDA issued draft guidance to accelerate approvals of highly individualized therapies targeting ultra-rare conditions. The proposed framework is intended to provide regulatory flexibility in situations where traditional randomized trials are not feasible due to very small patient populations.The guidance focuses on therapies that directly address the underlying genetic or biological cause of disease, including genome-editing and RNA-based treatments. Under the framework, sponsors may rely on natural history data and mechanistic evidence, rather than large clinical trials, to support effectiveness and safety.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for QURE was ‘extremely bullish’ amid a 1,230% surge in 24-hour message volume, while sentiment for RGNX remained ‘neutral’ amid ‘extremely low’ volumes.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/qure_ss_png_8cedeec116.webp" alt="qure ss.png" width="968" height="145"><figcaption>QURE sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/rgnx_ss_png_d5895f4888.webp" alt="rgnx ss.png" width="973" height="143"><figcaption>RGNX sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/murphylaw/message/646044348">said</a>, “I saw the interview again. Makary is not talking about Qure. We do not even have a BLA with FDA yet. This is a miracle treatment for Huntington's disease. I am loading up in the morning.<stembedurl>https://stocktwits.com/murphylaw/message/646044348</stembedurl>Another user said, “If people thought it could be RGNX, you would think RGNX would be down.”<stembedurl>https://stocktwits.com/kenny91655/message/646029219</stembedurl>While QURE stock fell 28% year-to-date, RGNX stock has declined 39% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? 

Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121.

Equity

<ul class="summary-bullets"><li>In an interview, Makary defended the FDA's recent, stricter stance on rare disease drug approvals.</li><li>He specifically mentioned a "product" where researchers drilled burr holes in patients' skulls to inject a therapy, which showed no benefit in a randomized trial and had associated morbidity.</li><li>While Leerink believes Makary was referring to Regenxbio's RGX-121, Stifel thinks he was referring to uniQure AMT-130.</li></ul>Shares of uniQure fell 32% on Thursday on the heels of comments by FDA Commissioner Marty Makary on CNBC on rare disease drug applications.In an interview with <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2026/02/26/fda-commissioner-dr-makary-on-rare-disease-therapy-approvals-internal-politics-at-the-agency.html">CNBC</a>, Makary defended the FDA's recent, stricter stance on rare disease drug approvals. He specifically mentioned a "product" where researchers drilled burr holes in patients' skulls to inject a therapy, which showed no benefit in a randomized trial and had associated morbidity.“I have a lot of sympathy for those patients. There's nothing out there to offer them, but we're not going to go ahead and approve something like that that has morbidity associated with it,” he said.<h2 class="st-heading-2">uniQure’s AMT-130</h2>Makary’s comments were deemed a reference to uniQure’s Huntington’s disease gene therapy<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-tumbles-after-fda-meeting/cL2NBqhR3zq"> AMT-130</a>, sending shares spiralling.In November, uniQure said that it no longer believes that the FDA considers data from an early-to mid-stage trial of its investigational gene therapy sufficient for approval.The company recently met with the agency, and although the minutes of the meeting have not been received, the company believes that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval, it then said.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">Analysts Chip In</h2>Leerink, however, noted that the comments seem to point to a drug that had been officially reviewed and rejected, and highlights that Makary also mentioned the drug had morbidity associated with it and there was no cure. The firm believes this is referring to Regenxbio's (RGNX) RGX-121, and not AMT-130.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rgnx-shares-plummet-after-hours-today/cZbxnumR4ot">refused </a>to approve Regenxbio’s Hunter syndrome gene therapy earlier this month citing insufficient evidence of effectiveness. The company said it is planning to meet with the FDA to address the complete response letter, gather expert input and longer-term clinical data to better define the eligible patient population, and work toward resubmitting its application as quickly as possible.<h2 class="st-heading-2">Stifel Believes Differently</h2>Stifel, meanwhile, said that it can see why uniQure's shares are lower on comments from FDA commissioner Makary. Makary was defensive of FDA's approach broadly, as he appeared to maybe refer to the AMT-130 program as an example of something his FDA didn't get behind.To be clear, his specific commentary might/might not have been referring to AMT-130 since uniQure never received an actual complete response letter, the firm noted. While some seem to think Makary was referring to Regenxbio's (RGNX) RGX-121, this doesn't really make sense to Stifel since he describes a drug that didn't beat a control arm, and the Regenxbio study in Hunter was single-arm, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around QURE stock &nbsp;rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.Sentiment around RGNX stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> has risen 45% over the past 12 months, while <a href="https://stocktwits.com/symbol/RGNX">RGNX</a> gained 25%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/akba-shares-rise-on-clinical-pipeline-optimism-as-anemia-drug-gains-traction/cZTG1NQRIR2">AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy  

Following the comments, shares of both Regenxbio and uniQure traded in the red. 

QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE...

uniQure (NASDAQ:QURE) Shares Gap Down - Should You Sell?

uniQure (NASDAQ:QURE) Shares Gap Down - Should You Sell...

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$15.63
Prev Close	$17.12
Open	$17.08
Dividend Yield	0.00%
50-Day Moving Average	$23.46
Beta	1.46
Avg. Volume	1.88M
PE Ratio	-3.56

52-Week High	$71.50
52-Week Low	$7.76
Market Capitalization	$962.87M
EPS (Annual)	-$4.92
Price to Book	4.25
Revenue Per Employee	$129,755.98

QURE
uniQure NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News

QUREuniQure NV